| Authors: |
Pretz C; Guardant Health, Inc., Redwood City, CA, USA. cpretz@guardanthealth.com., Fuentes-Antrás J; NEXT Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain., Main S; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Dou A; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Shah E; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Van de Laar E; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Weipert CM; Guardant Health, Inc., Redwood City, CA, USA., Lin B; Guardant Health, Inc., Redwood City, CA, USA., Das A; Guardant Health, Inc., Redwood City, CA, USA., Amir E; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Nadler MB; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Yu C; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Berman HK; Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Canada., Siu LL; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Bedard PL; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Elliott MJ; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology, Yale Cancer Center, New Haven, CT, USA., Cescon DW; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada. |
